Takeda will open a new plant in Singen, Germany that will manufacture the company’s dengue vaccine candidate, TAK-003. Phase III results show the vaccine is effective against the mosquito-borne virus. 

The company began construction in 2016 and invested approximately $140 million to build the facility. It will employ as many as 200 people once operational. The plant is currently ready for packaging production and production of the vaccine, once approved.
 
In a placebo-controlled study that included more than 20,000 children, the vaccine was approximately 80% effective in protecting against dengue infection. The vaccine was generally well tolerated with no significant safety risks observed to date. According to the company Dengue causes about 390 million infections and 20,000 deaths a year.